GlassScriptPhysician profile
Esha Cannon
NPI 1700183522
$1,712.81
in general payments reported to CMS, 2019-2025
34 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.83 · 2020: $13.18 · 2021: $26.92 · 2022: $55.88 · 2023: $46.66 · 2024: $67.86 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $299.57 | 2022-2025 | |
| Glaxosmithkline, LLC. | $164.42 | 2024-2025 | Ojjaara, Blenrep, Jemperli |
| Astrazeneca Pharmaceuticals LP | $98.93 | 2025 | Tagrisso, Imfinzi |
| Gilead Sciences, INC. | $79.64 | 2025 | Trodelvy |
| Stemline Therapeutics INC. | $65.63 | 2025 | Orserdu |
| Abbvie INC. | $64.03 | 2025 | |
| Kite Pharma, INC. | $63.90 | 2024-2025 | Yescarta |
| Incyte Corporation | $58.80 | 2025 | Zynyz, Monjuvi |
| Astellas Pharma US INC | $57.92 | 2025 | Vyloy, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $52.20 | 2025 | |
| Beone Medicines USA, INC. | $48.55 | 2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $47.84 | 2025 | Opdivo |
| Daiichi Sankyo INC. | $46.88 | 2023-2025 | Datroway, Enhertu |
| Alexion Pharmaceuticals, INC. | $46.70 | 2022-2025 | Ultomiris |
| Pfizer INC. | $44.66 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $42.67 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.51 | 2025 | Ninlaro |
| Regeneron Healthcare Solutions, INC. | $33.11 | 2025 | Libtayo |
| Celgene Corporation | $30.96 | 2025 | Reblozyl |
| Adc Therapeutics America, INC. | $30.71 | 2025 | |
| Legend Biotech USA INC. | $29.83 | 2025 | Carvykti |
| Genentech USA, INC. | $29.25 | 2022-2025 | Venclexta |
| Pharmaessentia USA Corporation | $29.19 | 2025 | Besremi |
| Genzyme Corporation | $24.57 | 2025 | |
| Geron Corporation | $23.53 | 2025 | Rytelo |
| Exelixis INC. | $22.59 | 2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $22.04 | 2025 | Lynparza, Keytruda, Welireg |
| Boston Scientific Corporation | $19.73 | 2024 | Spaceoar Vue System - 10ml |
| Agios Pharmaceuticals, INC. | $19.51 | 2025 | Pyrukynd |
| Adaptive Biotechnologies Corporation | $19.00 | 2025 | Clonoseq |
| Eisai INC. | $17.87 | 2025 | |
| Janssen Biotech, INC. | $16.15 | 2025 | Tecvayli |
| Jazz Pharmaceuticals INC. | $14.88 | 2021 | |
| Taiho Oncology, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esha Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.